Matter of life and death: The pharmacological approaches targeting apoptosis in brain diseases

Virve Cavallucci, Marcello D'Amelio

Research output: Contribution to journalArticle

Abstract

Neurodegenerative diseases that include amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, stroke, brain trauma and spinal cord injury, are associated with the inappropriate activation of a neuronal cell-suicide program called apoptosis. Given that central nervous system tissue has very limited regenerative capacity it is of extreme importance to limit the damage caused by neuronal death. During the past decade, considerable progress has been made in understanding the process of apoptosis and, significantly, a number of studies have shown that a variety of small molecules can activate or inhibit cell death by acting on crucial checkpoints of apoptosis. Here, we review evidence linking apoptosis to brain diseases and discuss how knowledge of the mechanisms of cell death has led to novel therapeutic strategies.

Original languageEnglish
Pages (from-to)215-229
Number of pages15
JournalCurrent Pharmaceutical Design
Volume17
Issue number3
DOIs
Publication statusPublished - 2011

Fingerprint

Brain Diseases
Pharmacology
Apoptosis
Cell Death
Nerve Tissue
Huntington Disease
Amyotrophic Lateral Sclerosis
Spinal Cord Injuries
Neurodegenerative Diseases
Suicide
Parkinson Disease
Alzheimer Disease
Central Nervous System
Stroke
Therapeutics

Keywords

  • Anti-apoptotic therapies
  • Cell death
  • Mitochondria
  • Neurodegenerative diseases
  • Oxidative stress

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Matter of life and death : The pharmacological approaches targeting apoptosis in brain diseases. / Cavallucci, Virve; D'Amelio, Marcello.

In: Current Pharmaceutical Design, Vol. 17, No. 3, 2011, p. 215-229.

Research output: Contribution to journalArticle

@article{d4d8c5a6e04a4e72b1a4789b5ac4bbc6,
title = "Matter of life and death: The pharmacological approaches targeting apoptosis in brain diseases",
abstract = "Neurodegenerative diseases that include amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, stroke, brain trauma and spinal cord injury, are associated with the inappropriate activation of a neuronal cell-suicide program called apoptosis. Given that central nervous system tissue has very limited regenerative capacity it is of extreme importance to limit the damage caused by neuronal death. During the past decade, considerable progress has been made in understanding the process of apoptosis and, significantly, a number of studies have shown that a variety of small molecules can activate or inhibit cell death by acting on crucial checkpoints of apoptosis. Here, we review evidence linking apoptosis to brain diseases and discuss how knowledge of the mechanisms of cell death has led to novel therapeutic strategies.",
keywords = "Anti-apoptotic therapies, Cell death, Mitochondria, Neurodegenerative diseases, Oxidative stress",
author = "Virve Cavallucci and Marcello D'Amelio",
year = "2011",
doi = "10.2174/138161211795049705",
language = "English",
volume = "17",
pages = "215--229",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Matter of life and death

T2 - The pharmacological approaches targeting apoptosis in brain diseases

AU - Cavallucci, Virve

AU - D'Amelio, Marcello

PY - 2011

Y1 - 2011

N2 - Neurodegenerative diseases that include amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, stroke, brain trauma and spinal cord injury, are associated with the inappropriate activation of a neuronal cell-suicide program called apoptosis. Given that central nervous system tissue has very limited regenerative capacity it is of extreme importance to limit the damage caused by neuronal death. During the past decade, considerable progress has been made in understanding the process of apoptosis and, significantly, a number of studies have shown that a variety of small molecules can activate or inhibit cell death by acting on crucial checkpoints of apoptosis. Here, we review evidence linking apoptosis to brain diseases and discuss how knowledge of the mechanisms of cell death has led to novel therapeutic strategies.

AB - Neurodegenerative diseases that include amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, stroke, brain trauma and spinal cord injury, are associated with the inappropriate activation of a neuronal cell-suicide program called apoptosis. Given that central nervous system tissue has very limited regenerative capacity it is of extreme importance to limit the damage caused by neuronal death. During the past decade, considerable progress has been made in understanding the process of apoptosis and, significantly, a number of studies have shown that a variety of small molecules can activate or inhibit cell death by acting on crucial checkpoints of apoptosis. Here, we review evidence linking apoptosis to brain diseases and discuss how knowledge of the mechanisms of cell death has led to novel therapeutic strategies.

KW - Anti-apoptotic therapies

KW - Cell death

KW - Mitochondria

KW - Neurodegenerative diseases

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=79955978036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955978036&partnerID=8YFLogxK

U2 - 10.2174/138161211795049705

DO - 10.2174/138161211795049705

M3 - Article

C2 - 21348825

AN - SCOPUS:79955978036

VL - 17

SP - 215

EP - 229

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 3

ER -